Document is current

Any future updates will be listed below

FDA approvals in 2024: new options for patients across cancer types and therapeutic classes

Crossref DOI link: https://doi.org/10.1038/s41571-025-01018-w

Published Online: 2025-04-11

Published Print: 2025-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark